I appreciate the CE Mark process has taken longer than we may
have anticipated and indicated to shareholders, however, we
remain confident of obtaining a CE Mark in the near term. This is
based on feedback and dialogue received and the input of our
regulatory advisers. Looking ahead to the 2017
financial year, one of our key focuses as a Company is to obtain
the CE Mark and to commence the commercial sales of OncoSil™
in the European Union.
Sounds Promising
Better hurry up
Only 8 months left in 2017 financial year
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.080(6.50%) |
Mkt cap ! $15.71M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $38.64K | 31.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8606 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 587 | 1 |
View Market Depth
| Last trade - 13.34pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |